Biocon, Mylan get USFDA’s approval for insulin glargine injection ‘Semglee’

12 Jun 2020 Evaluate

Biocon and Mylan N.V. have received an approval from the US Food and Drug Administration (USFDA) for the New Drug Application (NDA) for Semglee (insulin glargine injection), in vial and prefilled pen presentations, to control high blood sugar in adults with type 2 diabetes and adult and pediatric patients with type 1 diabetes. Semglee has an identical amino acid sequence to Sanofi’s Lantus and is approved for the same indications.

Semglee, codeveloped by Mylan and Biocon Biologics, was approved as a drug product under the 505(b)(2) NDA pathway and is now deemed a biologic under section 351(a) in accordance with the Biologics Price Competition and Innovation Act in line with other insulin products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovationdriven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

365.25 -1.15 (-0.31%)
27-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.30
Dr. Reddys Lab 1240.00
Cipla 1312.85
Zydus Lifesciences 893.45
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×